Navigation Links
WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
Date:6/22/2009

SHANGHAI, June 22 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Felix Hsu has been appointed Senior Vice President of WuXi AppTec U.S.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Mr. Hsu worked at Medtronic for 14 years in positions of increasing responsibility. He has broad experience as a product manager and business leader, serving as Director of Heart Valve Worldwide Marketing; Vice President of Business Excellence; Vice President of Cardiac Surgery for Asia Pacific, based in Hong Kong; and Vice President of Supply Chain Integration based in Minneapolis. Prior to working at Medtronic, he served in product management, sales management, and strategic planning roles at Abbott Laboratories and as a business manager at Sabratek. In these roles, he was successful in driving revenue growth through effective product management and in implementing strategies to improve operational excellence and reduce costs.

In his new role, Mr. Hsu will be responsible for WuXi's U.S. business. A significant portion of U.S. revenues are derived from serving the medical device industry, where Mr. Hsu has extensive experience. He will report to Edward Hu, Chief Operating Officer, acting Chief Financial Officer, and current head of U.S. operations.

"I am very pleased to welcome Felix on board as we continue to strengthen our U.S. management team," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Our U.S. operations offer a range of testing services critical to the s
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... safety and efficacy of Albuferon administered every four weeks in ... hepatitis C - , , ROCKVILLE, Md., June 19 ... today announced that Novartis has completed enrollment and initial dosing ... and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination ...
... Has Tentative FDA Approval and Expects Final Approval Shortly -- ... Inc. (NYSE: HSP ), the world leader in ... for the District of New Jersey has granted summary judgment ... chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from ...
... WalkMS Participants - , , NEW YORK, June ... family, and other people living with multiple sclerosis, Saatchi & ... component of the "I Walk Because" program. The site ... social media applications. , , The site, ...
Cached Biology Technology:Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3I Walk Because Program Gives Consumers a Voice 2I Walk Because Program Gives Consumers a Voice 3
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... IOF and ESCEO will be staging the ... largest bone meeting in Europe, to be held ... the pre-registration deadline of March 7, 2011 fast ... registration to the 1st IOF-ESCEO Pre-Clinical Symposium (from ...
... Scientists have published results that will forever change the ... replication and the prevention of DNA damage. ... to many problems including cancers. Researchers, funded by the ... Wellcome Trust and working at The University of Nottingham, ...
... Chase, MDA recent study accepted for publication in ... for the first time that maternal fructose intake during ... endocrinology. Fructose is a simple sugar found naturally ... dietary fructose, particularly due to calorically sweetened beverages, are ...
Cached Biology News:8 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2Collisions of protein machines cause DNA replication derailment 2Maternal fructose intake impacts female and male fetuses differently 2
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
... John M. Walker (1996) • This ... techniques for studying proteins and peptides. ... detailed, step-by-step instruction, timesaving troubleshooting tips, ... lists of reagents and suppliers. Topics ...
...
Biology Products: